Looking to expand your partner network with leading companies like Servier? Consider joining Inpart's global network for free.
News and Trends 3 Nov 2022
Servier and OSE Immunotherapeutics complete enrollment in Sjögren’s syndrome trial
Servier and French biotech company OSE Immunotherapeutics SA have completed patient enrollment in a phase 2a clinical trial evaluating the efficacy and safety of monoclonal antibody OSE-127/S95011 in primary Sjögren’s syndrome. The international, randomized, double-blind, placebo-controlled, phase 2a study is designed to evaluate the efficacy and tolerance of the monoclonal antibody OSE-127/S95011 in primary Sjögren’s […]
